Boothbay Fund Management LLC Raises Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Boothbay Fund Management LLC raised its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 8.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 251,774 shares of the biopharmaceutical company's stock after acquiring an additional 18,718 shares during the quarter. Boothbay Fund Management LLC owned approximately 0.44% of Agios Pharmaceuticals worth $8,273,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Virtus ETF Advisers LLC grew its position in shares of Agios Pharmaceuticals by 30.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 9,160 shares of the biopharmaceutical company's stock worth $301,000 after buying an additional 2,118 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in shares of Agios Pharmaceuticals during the 4th quarter worth $9,957,000. Hsbc Holdings PLC boosted its position in Agios Pharmaceuticals by 532.9% during the fourth quarter. Hsbc Holdings PLC now owns 30,584 shares of the biopharmaceutical company's stock valued at $1,003,000 after purchasing an additional 25,752 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Agios Pharmaceuticals by 236.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,286 shares of the biopharmaceutical company's stock valued at $338,000 after purchasing an additional 7,230 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its position in Agios Pharmaceuticals by 5.9% during the fourth quarter. MetLife Investment Management LLC now owns 34,579 shares of the biopharmaceutical company's stock valued at $1,136,000 after purchasing an additional 1,916 shares in the last quarter.

Insiders Place Their Bets

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the transaction, the director now owns 149,220 shares of the company's stock, valued at $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO traded up $0.43 during midday trading on Thursday, hitting $30.12. The company's stock had a trading volume of 235,656 shares, compared to its average volume of 706,674. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58. The business's fifty day simple moving average is $30.00 and its two-hundred day simple moving average is $37.99. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of 2.66 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price target for the company. StockNews.com lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $56.57.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.